



22nd September 2018

(1) BSE Limited
Listing Department
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001

(2) National Stock Exchange of India Ltd
Listing Department
Exchange Plaza, 5th Floor,
Plot no. C/1, G Block
Bandra Kurla Complex,
Bandra (East), Mumbai – 400 051

Scrip Code: 500087

Scrip Code: CIPLA EQ

(3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg

Dear Sir / Madam,

Sub: Press Release

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed press release dated 22nd September 2018 titled “**Cipla receives final approval for generic version of Impax Laboratories, Inc.’s Albenza® (Albendazole Tablets 200mg)**”.

Kindly acknowledge the receipt.

Thank you.

Yours faithfully,
For Cipla Limited

Rajendra Chopra
Company Secretary

Encl: as above

Prepared by: Karan Tanna



Press Release

Cipla receives final approval for generic version of Impax Laboratories, Inc.'s Albenza® (Albendazole Tablets 200mg)

Mumbai, India, September 22, 2018: Cipla Limited ("Cipla") today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Albendazole Tablets 200mg from the United States Food and Drug Administration (US FDA).

Cipla's Albendazole Tablets 200mg is AB-rated generic therapeutic equivalent version of Impax Laboratories, Inc.'s, Albenza®. It is an anthelmintic drug indicated for use in Treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, *Taenia solium* and cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, *Echinococcus granulosus*.

According to IQVIA (IMS Health), Albenza® had US sales of approximately \$99M for the 12-month period ending July 2018. The product is available for shipping immediately.

About Cipla:

Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, anti-retroviral, urology, cardiology and CNS segments are well-known. Our 44 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using

cutting-edge technology platforms to cater to our 80+ markets. Cipla is ranked 3rd largest in pharma in India (IQVIA MAT Mar'18), 4th largest in the pharma private market in South Africa (IQVIA MAT Jun'18), and is among the most dispensed generic players in the US. For over eight decades, making a difference to patients has inspired every aspect of Cipla's work. Our paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility and affordability to the centre of the movement. A responsible corporate citizen, Cipla's humanitarian approach to healthcare in pursuit of its purpose of 'Caring for Life' and deep-rooted community links wherever it is present make it a partner of choice to global health bodies, peers and all stakeholders. For more, please visit www.cipla.com, or click on [Twitter](#), [Facebook](#), [LinkedIn](#).

For queries, please contact:

Corporate Communications

Heena Kanal

E-Mail: CorpComm@cipla.com

Investor Relations

Naveen Bansal

E-Mail: Investor.Relations@cipla.com